{"title": "Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA\u00ae When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents", "author": null, "url": "https://www.fiercepharma.com/vaccines/pfizer-s-phase-2-study-demonstrates-safety-tolerability-and-immunogenicity-of-trumenba%C2%AE", "hostname": "fiercepharma.com", "description": "Data presented for the first time at IDWeek 2015 in San Diego Friday, October 9, 2015 - 1:45pm EDT Pfizer Inc. (NYSE:PFE) announced today that researchers presented for the first time data... | Data presented for the first time at IDWeek 2015 in San Diego Friday, October 9, 2015 - 1:45pm EDT Pfizer Inc. (NYSE:PFE) announced today that researchers presented for the first time data...", "sitename": "FiercePharma", "date": "2015-10-12", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}